Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-K/A
Source: 0001731122-25-000252
Chunk: 121

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-K/A
Chunk 121
---
   |     | $    |           — |   |
| Common shares issued upon acquisition                                       |     | $                   | 136,001,631 |   |     | $    |           — |   |
| Contingent consideration issued upon acquisition                            |     | $                   |  20,557,500 |   |     | $    |           — |   |
| Common shares issued upon settlement of debt                                |     | $                   |   9,582,912 |   |     | $    |           — |   |
| Earn out shares issued in settlement of contingent liability                |     | $                   |  11,295,683 |   |     | $    |           — |   |
| Options issued in settlement of debt                                        |     | $                   |     489,000 |   |     | $    |           — |   |
| Settlement of notes payable                                                 |     | $                   |     418,503 |   |     | $    |           — |   |

<div align='center'>The accompanying notes are an integral part of these consolidated financial statements.

F-9

RENOVARO INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</div>

NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Business–On February 13, 2024, the Company changed its corporate name from Renovaro Biosciences Inc. to Renovaro Inc.
(“Renovaro”, and together with its subsidiaries, the “Company”, “we” or “us”). In August
2023, the Company changed its corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc. The Company is an AI-driven
healthcare technology company that, if it can generate sufficient funding, will also continue to engage in the research and development
of pharmaceutical and biological products for the treatment of cancer and HIV with the intent to manufacture said products. On February
13, 2024, Renovaro Inc. acquired GEDi Cube Intl Ltd and its subsidiaries (“Renovaro Cube”), as a wholly owned subsidiary
pursuant to a stock purchase agreement.

Basis of Presentation–The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States
of America (“U.S. GAAP”) and follows the rules and regulations of the U.S. Securities and Exchange Commission (“SEC